Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.

This model showed a trend toward growth inhibition with 8 and 16 mg/kg zanidatamab, but this model demonstrated progressive disease, without a statistically significant increase in time to tumor doubling with zanidatamab at any dose range ( Fig. 3E ).

also in 53,322 other papers